{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"MERMAID-1","nct_id":"NCT04385368","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mermaid-1-nct04385368. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"MERMAID-1","arms":[{"description":"Intravenous administration of Experimental and Standard of Care Therapy","label":"Durvalumab + SoC chemotherapy","type":"EXPERIMENTAL"},{"description":"Intravenous administration of Placebo and Standard of Care Therapy","label":"Placebo + SoC chemotherapy","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2023-08-31","type":"ACTUAL"},"conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":{"count":89,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Durvalumab + SoC chemotherapy","otherNames":["MEDI4736"],"type":"DRUG"},{"name":"Placebo + SoC chemotherapy","otherNames":["Placebo"],"type":"OTHER"}],"last_update":"2024-08-30","lead_sponsor":"AstraZeneca","official_title":"A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination With Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC (MERMAID-1)","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Disease-free Survival (DFS) in FAS (Using Investigator Assessments According to Response Evaluation Criteria in Solid Tumors 1.1 [RECIST 1.1])","timeFrame":"Every 12 weeks (q12w) ± 1 week until appearance of RECIST 1.1-defined disease recurrence or until primary DFS analysis, up to 33.28 months"}],"references":[],"start_date":{"date":"2020-07-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT04385368"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mermaid-1-nct04385368"}